Implant provides long-acting treatment for prostate cancer

Luteinizing hormone-releasing hormone (LHRH) agonists are a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for these therapies representing more than $1 billion in annual sales. The market is dominated by four-month and shorter depot injections and implants, such as leupro-lide acetate (Lupron, TAP Pharmaceuticals) for depot suspension and goserelin acetate (Zoladex, Astra Zeneca) implant.